Jasmin, Luzminda V.
HRN: 24-61-12 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/11/2024
CEFUROXIME 1.5GM (VIAL)
02/11/2024
02/17/2024
IVT
1.5g
Q8
T/C Osteosarcoma
Waiting Final Action
Indication: Empiric Type of Infection: Bone & JointSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes